Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

XFOR X4 Pharmaceuticals Inc

0.00 (0.00%)
May 27 2024 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 0
Bid Price 0.9031
Ask Price 0.94
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
X4 Pharmaceuticals Inc XFOR NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 0.9031 20:00:00
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
0 0 - 0.5723 - 2.575
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.9031 USD

X4 Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
150.56M 167.29M - 0 -101.17M -0.60 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

X4 Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No XFOR Message Board. Create One! See More Posts on XFOR Message Board See More Message Board Posts

Historical XFOR Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.900.9498990.860.9005631,112,3980.00310.34%
1 Month1.201.220.861.052,647,676-0.2969-24.74%
3 Months0.97941.600.821.193,485,778-0.0763-7.79%
6 Months0.7771.600.57231.032,714,0900.126116.23%
1 Year2.042.5750.57231.242,509,302-1.14-55.73%
3 Years9.499.700.57231.471,422,080-8.59-90.48%
5 Years17.1818.750.57231.75878,787-16.28-94.74%

X4 Pharmaceuticals Description

X4 Pharmaceuticals Inc is clinical-stage biopharmaceutical company. It is focused on restoring the immune system function by developing therapeutics for the treatment of rare diseases. Its molecule therapeutics are antagonists of chemokine receptor CXCR4, which have the potential to treat a broad range of rare diseases, including primary immunodeficiencies (PIs) and cancer. Its product candidate, X4P-001, has completed a Phase 2 trial in patients with a rare genetic PI called Warts. The company is also developing X4P-002, a CXCR4 antagonist that has properties that could enable penetration of the blood-brain barrier and provide appropriate therapeutic exposures to treat brain cancers, including glioblastoma multiforme.

Your Recent History

Delayed Upgrade Clock